New hope for Tough-to-Treat cancer: experimental drug enters human trials

NCT ID NCT06132113

Summary

This early-stage study is testing a new drug called BI 764532, given by IV along with standard chemotherapy, for adults with an aggressive type of neuroendocrine cancer. The main goal is to find the safest and most tolerable dose of the new combination. Researchers will also check if the treatment helps shrink tumors in patients whose cancer has a specific marker called DLL3.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital

    RECRUITING

    Aichi, Nagoya, 464-8681, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Akademiska hospital

    NOT_YET_RECRUITING

    Uppsala, 751 85, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Brussels, 1200, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HOP Louis Pradel

    NOT_YET_RECRUITING

    Bron, 69500, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitari Vall D Hebron

    RECRUITING

    Barcelona, 08035, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, 28046, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • INS Paoli-Calmettes

    RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • John Theurer Cancer Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinikum der Universität München AÖR

    NOT_YET_RECRUITING

    München, 81377, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, Chuo-ku, 104-0045, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Cancer Center Hospital East

    RECRUITING

    Chiba, Kashiwa, 277-8577, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwestern University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Osaka International Cancer Institute

    RECRUITING

    Osaka, Osaka, 541-8567, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sahlgrenska Universitetsjukhuset

    RECRUITING

    Gothenburg, 413 46, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitair Medisch Centrum Groningen

    RECRUITING

    Groningen, 9713 GZ, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Tübingen

    RECRUITING

    Tübingen, 72076, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.